Clinical trials of a new melanoma drug have begun

The Dobrobut medical network has announced the opening of enrollment in a clinical trial for patients with previously untreated stage III unresectable and stage IV melanoma.

Patients with the following conditions are eligible to participate in the study:

• confirmed stage III melanoma that cannot be surgically removed, or stage IV melanoma with internal organ involvement;
• no previous treatment with immunotherapy or targeted therapy.

Before being included in the study, each patient undergoes thorough screening, as not all forms of melanoma are suitable for participation, and certain health conditions may be a limitation.

Study participants receive:

• access to modern immunotherapeutic approaches;
• free highly specialized medical care;
• support from a research team led by researcher Maria Kukushkina;
• free examinations as specified in the protocol;
• transportation to the clinical base in Kyiv, organized and paid for by the study;
• confidentiality and ongoing medical support.

Participants will be randomly assigned to two groups: one will receive a registered immunotherapeutic drug, and the other will receive an investigational immunotherapeutic drug.

"It is fundamentally important for us that Ukrainian patients have access to innovative treatment methods on par with patients at leading clinics around the world. Clinical research is an established international practice that not only advances medicine but also provides people with modern therapeutic options within clear safety and control protocols. That is why Dobrobut is systematically developing clinical research and joining international oncology programs," says Maria Kukushkina, a research physician and head of the oncology service at the Dobrobut medical network.

If you or your loved ones would like more detailed information and to understand whether participation is right for you, we are always open to dialogue:

067-150-29-87 - Olga Zhmurko, Clinical Research Manager

clinicaltrials@med.dobrobut.com